Zoetis (NYSE:ZTS) Stock Rating Lowered by Zacks Research

Zoetis (NYSE:ZTS) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

ZTS has been the subject of a number of other research reports. Piper Sandler dropped their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday. Barclays decreased their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 1st. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research note on Friday. Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a report on Tuesday. Finally, UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $109.62.

Zoetis Trading Up 0.5%

Shares of ZTS stock opened at $75.23 on Monday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis has a 1-year low of $71.45 and a 1-year high of $160.48. The firm has a market capitalization of $31.54 billion, a PE ratio of 12.39, a P/E/G ratio of 1.29 and a beta of 0.73. The business’s fifty day moving average price is $76.57 and its 200 day moving average price is $99.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts forecast that Zoetis will post 6.19 EPS for the current fiscal year.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Zoetis by 12.9% in the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. BlackRock Inc. grew its stake in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after buying an additional 3,845,869 shares in the last quarter. J. Stern & Co. LLP boosted its holdings in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the period. State Street Corp lifted its position in shares of Zoetis by 0.8% during the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after purchasing an additional 149,382 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Zoetis by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Citigroup lowered its Zoetis price target from $112 to $96 but retained a Buy rating, implying substantial upside from recent levels. The continued Buy recommendation may provide support despite the more cautious valuation. Benzinga article
• Positive Sentiment: BNP Paribas Exane cut its target from $146 to $110 while maintaining an Outperform rating. The target still indicates significant potential appreciation, suggesting the firm views recent weakness as excessive relative to Zoetis’ long-term prospects. Tickerreport.com article
• Neutral Sentiment: JPMorgan reduced its Zoetis price target to $115, adding to the pattern of analysts recalibrating estimates without necessarily abandoning the investment case. JPMorgan price target article
• Neutral Sentiment: Piper Sandler lowered its target from $90 to $80 and assigned a Neutral rating. The target remains modestly above the recent share price, but the stance signals limited near-term conviction. Benzinga article
• Negative Sentiment: Recent coverage highlights leadership changes, competitive pressures and concerns surrounding Zoetis’ outlook. The company’s latest quarter also showed revenue down 0.2% year over year, while full-year 2026 EPS guidance of $6.15–$6.25 is below some analyst expectations, weighing on sentiment. ZTS Q2 Deep Dive article

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.